Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
Status:
Completed
Trial end date:
2021-08-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the addition of the investigation drug called
pembrolizumab (Keytruda®) to radiation therapy and bevacizumab (Avastin®) is safe and can
help with controlling the growth of tumors, in participants with recurrent high grade glioma.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute